- Home
- DMAC vs MFH Comparison
DMAC vs MFH Comparison
Compare DMAC & MFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MFH
- Stock Information
- Founded
- DMAC 2000
- MFH 2011
- Country
- DMAC United States
- MFH United States
- Employees
- DMAC N/A
- MFH N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MFH Finance: Consumer Services
- Sector
- DMAC Health Care
- MFH Finance
- Exchange
- DMAC Nasdaq
- MFH Nasdaq
- Market Cap
- DMAC 260.0M
- MFH 247.1M
- IPO Year
- DMAC N/A
- MFH N/A
- Fundamental
- Price
- DMAC $4.76
- MFH $3.57
- Analyst Decision
- DMAC Strong Buy
- MFH
- Analyst Count
- DMAC 4
- MFH 0
- Target Price
- DMAC $10.75
- MFH N/A
- AVG Volume (30 Days)
- DMAC 353.4K
- MFH 1.6M
- Earning Date
- DMAC 08-06-2025
- MFH 08-05-2025
- Dividend Yield
- DMAC N/A
- MFH N/A
- EPS Growth
- DMAC N/A
- MFH N/A
- EPS
- DMAC N/A
- MFH N/A
- Revenue
- DMAC N/A
- MFH N/A
- Revenue This Year
- DMAC N/A
- MFH N/A
- Revenue Next Year
- DMAC N/A
- MFH N/A
- P/E Ratio
- DMAC N/A
- MFH N/A
- Revenue Growth
- DMAC N/A
- MFH 125.92
- 52 Week Low
- DMAC $3.19
- MFH $1.03
- 52 Week High
- DMAC $6.82
- MFH $8.86
- Technical
- Relative Strength Index (RSI)
- DMAC 64.04
- MFH 45.53
- Support Level
- DMAC $4.81
- MFH $1.56
- Resistance Level
- DMAC $5.60
- MFH $3.55
- Average True Range (ATR)
- DMAC 0.45
- MFH 0.91
- MACD
- DMAC 0.11
- MFH -0.07
- Stochastic Oscillator
- DMAC 67.90
- MFH 37.50
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.